Journal for ImmunoTherapy of Cancer (Nov 2020)

279 Durvalumab after chemoradiotherapy for PD-L1 expressing inoperable stage III NSCLC impacts local-regional control and overall survival

Lukas Kaesmann,
Julian Taugner,
Chukwuka Eze,
Claus Belka,
Farkhad Manapov

Affiliations

Lukas Kaesmann: LMU University Hospital, Munich, Germany
Julian Taugner: LMU University Hospital, Munich, Germany
Chukwuka Eze: LMU University Hospital, Munich, Germany
Claus Belka: LMU University Hospital, Munich, Germany
Farkhad Manapov: LMU University Hospital, Munich, Germany

DOI: https://doi.org/10.1136/jitc-2020-SITC2020.0279
Journal volume & issue: Vol. 8, no. Suppl 3

Abstract

No abstracts available.

Published in Journal for ImmunoTherapy of Cancer

ISSN: 2051-1426 (Online)
Publisher: BMJ Publishing Group
Country of publisher: United Kingdom
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://jitc.bmj.com

About the journal